Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in a fireside chat and one-on-one meetings at the Cantor 2026 Global Healthcare Conference, scheduled for Sept. 9-11, 2026, in New York. President and CEO Seth Lederman, M.D., will present on Sept. 10 from 3:55-4:25 p.m. ET. A live webcast and replay will be available through the Investors section of the Tonix website.
This participation comes at a pivotal time for Tonix, as the company recently received approval for TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. The approval marks a significant milestone, positioning Tonix as a commercial-stage biotechnology company with a focus on central nervous system (CNS) and immunology treatments for areas of high unmet medical need.
Tonix's CNS commercial infrastructure supports its marketed products, including its acute migraine treatments, Zembrace SymTouch and Tosymra. The company is also exploring the full potential of TONMYA through Phase 2 clinical trials for major depressive disorder and acute stress disorder, which could expand its therapeutic reach. Additionally, the CNS pipeline includes TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, a rare genetic disorder.
Beyond CNS, Tonix is advancing immunology programs, such as TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection. These programs underscore the company's commitment to addressing significant unmet medical needs across multiple therapeutic areas.
The company's involvement in the Cantor conference provides a platform to engage with investors and industry peers, highlighting its progress and future direction. As Tonix continues to integrate TONMYA into the market and advance its pipeline, its presence at such conferences is crucial for maintaining visibility and confidence among stakeholders.
Tonix's product development candidates are investigational drugs or biologics; their efficacy and safety have not been established, and they have not been approved for any indication. The company's strategy focuses on maximizing the science behind its approved products while progressing its pipeline to bring innovative treatments to patients.
For more information about Tonix Pharmaceuticals, visit the company's newsroom at https://nnw.fm/TNXP. The latest news and updates are available there, and the full press release can be accessed at https://nnw.fm/hajiz.
